中金研报指出，AK112 头对头优于Keytruda，有望成为下一代IO治疗基石药物。该行维持2024年和2025 年盈利预测不变，维持“跑赢行业”评级。考虑到本次数据读出亮眼，基于DCF模型，该行上调目标价5.7%至70.00 港币，较当前股价45.2%空间。Akeso (09926) rose more than 15%, as of the time of publication, it rose by 15.56%, to 55.7 Hong Kong dollars, with a turnover of 1.84 billion Hong Kong dollars.
According to the Wisdom Financial APP, Akeso (09926) rose more than 15%, as of the time of publication, it rose by 15.56%, to 55.7 Hong Kong dollars, with a turnover of 1.84 billion Hong Kong dollars.
On the news front, recently, Akeso announced positive data from the phase III AK112-303 (HARMONi-2) study of IBI110 comparing to pembrolizumab (Keytruda) as monotherapy in first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression (PD-L1 TPS≥1%) at the 2024 World Lung Cancer Conference.
CICC's research report pointed out that IBI110 is superior to Keytruda and is expected to become the cornerstone drug for the next generation of IO therapy. The firm maintains its profit forecasts for 2024 and 2025, and the "outperform industry" rating. Considering the impressive data readout, the firm raised the target price by 5.7% to 70.00 Hong Kong dollars based on the DCF model, representing a 45.2% upside from the current stock price.
